arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Roivant Sciences Ltd.

ROIV
$36.83 ▼ -1.39 (-3.65%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
25 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Neutral
auto_awesome

Analytical Summary

Roivant Sciences Ltd. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $26.5B
Dividend Yield
Revenue Growth -33.5%
Op. Margin None
ROIC -8.5%
FCF / Share $-0.38
Trailing P/E
Price / Book 6.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.44M
↓ -33.5%
Net Income Profit after all expenses
$-189.84M
↑ +15.0%
FCF / Share Free cash flow per share
$-0.38
↓ -22.7%
Long-Term Debt Long-term obligations
$311.72M
↓ -22.7%

Health Breakdown

Returns
37
Cash Quality
90

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 25 quarters